drugset / Trial / NCT02889861
IMCgp100-401 Rollover Study
NaSingle-groupOpen-labelTreatment
Summary
IMCgp100-401 is a rollover study that is designed to provide continued access to IMCgp100 for eligible participants with advanced melanoma who have previously participated in an IMCgp100 study (parent study).
Timeline
- Start
- 2017-01-11
- Primary completion
- 2019-04-22
- Completion
- 2019-04-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tebentafusp | Protein / enzyme biologic | — | — |